Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

doi:10.1056/NEJMoa1006448

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

The New England journal of medicine - 28 Oct 2010

Kwak Eunice L, Bang Yung-Jue, Camidge D Ross, Shaw Alice T, Solomon Benjamin, Maki Robert G, Ou Sai-Hong I, Dezube Bruce J, Jänne Pasi A, Costa Daniel B, Varella-Garcia Marileila, Kim Woo-Ho, Lynch Thomas J, Fidias Panos, Stubbs Hannah, Engelman Jeffrey A, Sequist Lecia V, Tan WeiWei, Gandhi Leena, Mino-Kenudson Mari, Wei Greg C, Shreeve S Martin, Ratain Mark J, Settleman Jeffrey, Christensen James G, Haber Daniel A, Wilner Keith, Salgia Ravi, Shapiro Geoffrey I, Clark Jeffrey W, Iafrate A John

Abstract excerpt

BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors. We explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clinical trial of crizotinib (PF-02341066), an orally available small-molecule inhibitor of the ALK tyrosine kinase. METHODS: After screening...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oncogene Proteins, Fusion

Share to Administration, Oral

Share to Anaplastic Lymphoma Kinase

Share to Proto-Oncogene Proteins c-met

Share to Pyrazoles

Share to Pyridines

Share to Receptors, Growth Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 20979469
DOI: 10.1056/NEJMoa1006448
PMCID: PMC3014291

Genes

ALK
EML4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.PMID 20979469Read ↗

Targeting Anaplastic Lymphoma Kinase in Lung CancerSemantic proximity Read ↗

Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.Semantic proximity Read ↗

Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.Semantic proximity Read ↗

ALK in lung cancer: past, present, and future.Semantic proximity Read ↗

PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.Semantic proximity Read ↗

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancerSemantic proximity Read ↗

Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.Semantic proximity Read ↗

Crizotinib: an anaplastic lymphoma kinase inhibitor.Semantic proximity Read ↗

Anaplastic lymphoma kinase rearrangements in non-small-cell lung cancer: novel applications in diagnostics and treatment.Semantic proximity Read ↗

Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.Semantic proximity Read ↗

Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.